Side-Effects Management

Suboptimal Dosing of Filgrastim is Acceptable for Treatment of Chemotherapy-Induced Neutropenia

Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.

Read More ›

Managing Immune Checkpoint Inhibitor Side Effects:  Key Recommendations

The American Society of Clinical Oncology and the National Comprehensive Cancer Network collaborated to jointly develop a new guideline to help clinicians recognize and manage the range of side effects from immune checkpoint inhibitors.

Read More ›

The Challenges of Oral Cancer Drugs Use and Side-Effects Management

“There’s a human behind the patient, and he can tell us what he needs. He’s really the expert in the field,” Christine B. Boers-Doets, MSc, Netherlands Leiden University Medical Center, told attendees at the recent ESMO International Consensus Conference for Advanced Breast Cancer.

Read More ›

Immunotherapy is a hot topic in oncology, with hundreds of ongoing clinical trials. As more patients are treated with checkpoint inhibitors, nurses will play a key role in the management of these patients. Read More ›

The incidence of human papillomavirus (HPV)-associated oropharyngeal cancer is increasing. Patients treated for these cancers with radiation and chemotherapy are at increased risk for early and late side effects that diminish their quality of life, and nurses play a key role in coaching patients about living with these side effects. Read More ›

Real-world experience at The University of Texas MD. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis. Read More ›

Awareness of the adverse effects of immune checkpoint inhibitors and how to manage them was the focus of several presentations at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference. Read More ›

The results of a new study presented at the 2017 Genitourinary Cancers Symposium suggest that recent use of antibiotics may compromise the efficacy of immunotherapy. Read More ›

The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. Read More ›

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: